“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody “LEQEMBI ® ” (brand name in China: “??? ® ”, generic name: lecanemab) has been launched in China. LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aß aggregates (protofibrils*), as well as insoluble Aß aggregates (fibrils) which are a major component of Aß plaques in AD, thereby reducing both Aß protofibrils and Aß plaques in the brain. LEQEMBI is the world's first and only approved treatment shown to reduce the rate of disease
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIBAccesswire
- Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)Accesswire
- Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)PR Newswire
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIBAccesswire
- Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) ShareholdersAccesswire
BIIB
Earnings
- 4/25/24 - Beat
BIIB
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- BIIB's page on the SEC website